Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06909006
PHASE3

Semaglutide Treatment in Type 1 Diabetes

Sponsor: Nordsjaellands Hospital

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.

Official title: Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

122

Start Date

2025-10

Completion Date

2028-06

Last Updated

2025-08-08

Healthy Volunteers

No

Interventions

DRUG

Semaglutide 2.4mg

The active comparator of the intervention is s.c. Semaglutide injection once a week in increasing doses every month from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg and the placebo comparator is s.c. injection with a visually identical and same label pen as described for the active comparator

DRUG

Semaglutide placebo

Visually identical and same label as the active comparator intervention

Locations (1)

Nordsjaellands Hospital

Hillerød, Denmark, Denmark